Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.

January 9, 2022

Engineered human blood-brain barrier microfluidic model for vascular permeability analyses.

Nature Protocols
Cynthia HajalRoger D Kamm
January 8, 2022

The skeletal muscle relaxer cyclobenzaprine is a potent non-competitive antagonist of histamine H1 receptors.

The Journal of Pharmacology and Experimental Therapeutics
Kirti SinghNader H Moniri
January 3, 2022
Open Access

The Bradykinin B2 Receptor Agonist (NG291) Causes Rapid Onset of Transient Blood-Brain Barrier Disruption Without Evidence of Early Brain Injury.

Frontiers in Neuroscience
Sergio R Rodríguez-MassóAntonio Henrique Martins
December 25, 2021

Drug Delivery Systems and Strategies to Overcome the Barriers of Brain.

Current Pharmaceutical Design
Yogesh GargAmit Bhatia
December 24, 2021
Open Access

Delivery of Toxins and Effectors by Bacterial Membrane Vesicles.

Adrian MacionRenata Godlewska
December 12, 2021

A Compartmental Model for the Iron Trafficking Across the Blood-Brain Barriers in Neurodegenerative Diseases.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society
E FiciaraC Guiot
December 11, 2021
Open Access

Recent Advances in Biological Activity, New Formulations and Prodrugs of Ferulic Acid.

International Journal of Molecular Sciences
Monika Stompor-Gorący, Maciej Machaczka
December 8, 2021

Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier.

Free Radical Biology & Medicine
Barrett D Allen, Charles L Limoli
November 29, 2021
Open Access

Proteome of the Luminal Surface of the Blood-Brain Barrier.

Jennifer J HillDanica B Stanimirovic
November 26, 2021
Open Access

Comprehensive Mapping of the Cell Response to Borrelia bavariensis in the Brain Microvascular Endothelial Cells in vitro Using RNA-Seq.

Frontiers in Microbiology
Zuzana TkáčováMangesh Bhide
November 14, 2021

Chemical Approaches for Studying the Biology and Pharmacology of Membrane Transporters: The Histidine/Large Amino Acid Transporter SLC7A5 as a Benchmark.

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Mariafrancesca ScaliseCesare Indiveri
November 12, 2021

Potential of different cells-derived exosomal microRNA cargos for treating spinal cord injury.

Journal of Orthopaedic Translation
Dayu PanShiqing Feng
October 22, 2021

Sustained A1 Adenosine Receptor Antagonist Drug Release from Nanoparticles Functionalized by a Neural Tracing Protein.

ACS Chemical Neuroscience
Md Musfizur HassanGuangzhao Mao
October 23, 2021

The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics.

The FEBS Journal
Filipa D OliveiraMiguel A R B Castanho

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved